AI in Global Value Dossiers: Automating Evidence Synthesis and Authoring
Global Value Dossiers (GVDs) are essential for market access, but traditional authoring is slow, fragmented, and resource-intensive. Discover what GVDs are, why the process breaks down, and how AI is helping pharma teams create faster, more compliant dossiers.
.jpg)
A therapy clears regulatory approval. The science holds up, the safety data is clean, and the launch team is ready to move. Then market access hits a wall that has nothing to do with clinical evidence and everything to do with how that evidence gets packaged, translated, and defended in front of dozens of payers and HTA bodies across dozens of markets. The document at the center of that fight is the Global Value Dossier, and for most companies, building one still takes four to six months of manual work per asset.
What a Global Value Dossier Actually Does
A Global Value Dossier, or GVD, is the master evidence document pharma companies use to communicate a therapy's clinical, economic, and humanistic value to the people who decide whether patients get access to it: payers, Health Technology Assessment bodies, and Joint Clinical Assessment reviewers across the EU. It typically bundles clinical efficacy and safety data, health economic model outputs like cost-effectiveness and budget impact, real-world evidence supporting comparative value claims, alignment to the Target Product Profile, and payer-facing narratives built to answer objections before they're raised.
Once the global version exists, individual markets adapt it into Local Value Dossiers tailored to country-specific HTA templates, whether that's NICE's format in the UK, IQWiG's in Germany, or HAS's in France. Increasingly, teams are also building toward JCA-ready packages under the EU's Joint Clinical Assessment framework, which has required harmonized, standardized evidence submissions since 2025.
Five Bottlenecks That Turn Dossier Creation Into a Six-Month Project
Manual drafting eats the calendar first. Medical writers re-author substantially similar sections for every market cycle, which extends time-to-submission on documents that are, in substance, minor variations of the same global narrative.
Evidence lives everywhere except where it's needed. Clinical, economic, and real-world evidence gets scattered across files, systems, and formats, so there's no reliable way to trace a claim back to its source, let alone confirm that source still supports the claim in a new market.
Health economic models get rebuilt instead of reused. Assumptions, inputs, and narratives are recreated from scratch for every local adaptation, multiplying both the workload and the odds that something doesn't translate cleanly.
Evidence gaps show up at the worst possible time. Gaps in supporting evidence tend to surface during in-market review or localization, which is the most expensive and time-pressured point in the entire process to discover them.
The handoff between global and local runs on folders and email. Without a shared source of truth, coordinating dozens of parallel market adaptations turns into a version-control problem no one fully owns.
Why AI Doesn't Mean Removing the Medical Writer
The shift underway in GVD authoring isn't about letting AI write the dossier unsupervised. It's about AI drafting and structuring the first pass while medical writers and HEOR leads keep final ownership of every claim. A well-built GVD co-pilot works across six connected capabilities that reinforce each other:
AI-driven evidence and writing automates first-draft generation for dossier sections, producing payer-ready narratives directly from ingested clinical and RWE evidence, so writers start from a structured draft instead of a blank page.
TPP and payer alignment checks that every value narrative tracks back to the Target Product Profile and stays within the compliance boundaries of each target HTA body, catching misalignment before it reaches review.
Embedded economics captures health economic model assumptions, outputs, and narratives with a full audit trail, meaning market adaptations can reuse governed model logic instead of rebuilding it from zero.
Templates and modularity give writers pre-built, HTA-aligned templates with reusable content blocks by market, cutting the formatting and structural work out of every cycle.
The governed evidence layer structures evidence once and links it to every claim and section across the dossier and its local adaptations, so gap checks happen automatically during drafting rather than getting discovered by a reviewer weeks later.
Human-in-the-loop review stays the final control point throughout. AI produces first drafts and surfaces evidence; SMEs validate, annotate, and formally approve every section before anything moves forward.
Four Reasons This Approach Is Gaining Ground Fast
1. It compresses timelines without compressing oversight. Organizations using AI-assisted GVD authoring report up to 70% faster GVD creation and a 30 to 50% reduction in medical writing time, while human sign-off remains mandatory at every stage.
2. It catches problems while they're still cheap to fix. Evidence gaps and version inconsistencies get surfaced earlier, during drafting and TPP alignment, instead of during in-market HTA review when a fix means renegotiating a submission timeline.
3. It stops rebuilding work that already exists. Reused model assumptions and governed evidence mean local teams adapt existing logic instead of recreating it market by market.
4. It gives global and local teams one shared source of truth. The fragmented file-and-email handoff gets replaced by a single, traceable evidence layer that every market draws from.
How GVD, LVD, and JCA Fit Together
The GVD is the master document, built once and owned centrally. The LVD is a market-specific adaptation, mapped to a local HTA template. The JCA is the EU's centralized clinical assessment process, expanding across more indications through 2030, and it requires evidence submissions that are harmonized across member states from the start. A governed, AI-assisted evidence layer matters most exactly at these connection points, where reused evidence and model assumptions save the most rework and reduce the most risk.
Bringing It All Together: Building GVDs That Keep Pace With Rising HTA Standards
Global Value Dossiers were built to be the single source of truth for how a therapy's value gets communicated, but for most organizations, they're still produced the slowest, most manual way possible. As HTA standards rise and payer scrutiny intensifies, that gap between what a GVD is supposed to do and how it actually gets built is only getting more expensive to ignore.
Agilisium's Value Dossier Agent is built around exactly this problem: an AI co-pilot for GVD, HTA, and JCA authoring that keeps medical writers and HEOR teams in full control while removing the repetitive drafting and evidence-hunting work that has made dossier creation slow for years.
Partner with us to see how a governed, AI-assisted approach to GVD authoring can cut months out of your next submission cycle without cutting corners on compliance.
.jpg)
.jpg)
%20(7).avif)
%20(5).avif)
.avif)
